Have you ever looked at a hospital bill and thought, wait, who actually paid for that? I had that feeling again after reading through a federal audit on organ acquisition. The headline number is blunt. Medicare spent an estimated $380 million on human organs that were either transplanted into people without Medicare coverage or never transplanted at all. That is not a rounding error. That is a multi-year pattern sitting inside a reimbursement rule that hospitals were told to follow.
What The Audit Actually Found
Federal law is reasonably clear on paper. Medicare is supposed to cover organ acquisition costs when the organ is used in a Medicare-covered transplant. Kidneys, hearts, lungs, and other organs removed after a donor dies can generate large hospital costs. Those costs get billed. The problem is not that hospitals invented a secret scheme in a back room. The problem is older guidance that told hospitals to assume an organ sent to a transplant center would eventually go to a Medicare patient. They did not have to confirm that it did.
Auditors sampled 180 cases of organs that hospitals reported as Medicare-eligible between 2017 and 2022. Fifty-five of those organs were not used in Medicare-covered transplants, yet Medicare still paid about $2.8 million for that slice of the sample. Scale that up and the inspector general estimated $379.9 million over six years. I keep coming back to that figure because it is large enough to matter and small enough, in a multi-trillion-dollar program, to hide in plain sight.
Medicare should only bear those costs when the organ is used in a Medicare-covered transplant.
Of the 55 problem cases in the sample, 43 organs went to patients whose transplants were not covered by Medicare. Another 11 were discarded or used for research. One supposed donor was still alive. That last detail sounds almost like a punchline until you remember someone billed the public program for it. In my experience, the most revealing audits are the ones that mix ordinary paperwork errors with structural incentives. This one has both.
How The Assumption Became Policy
Decades-old guidance from the agency that runs Medicare told hospitals they could treat an organ as Medicare-eligible if it was sent onward. No final check. No confirmation that the recipient was a Medicare patient. No requirement to claw the payment back if the organ went somewhere else. If you design a payment system that way, you should not be shocked when the books drift.
Perhaps the most interesting aspect is how long this sat in the open. Officials already flagged the loophole in 2021 and floated a rule change. Hospitals warned they could lose revenue. The change was dropped. Four or five years later, the same structure is still producing the same kind of bill. That is not a mystery of medicine. That is a mystery of incentives.
I do not think every hospital administrator sat down and said, let’s soak taxpayers. Most people in these departments follow the manual they are given. When the manual says assume Medicare, they assume Medicare. Auditors even declined to recommend recovering the $380 million estimate because hospitals generally followed that guidance. They did recommend recovering $154,210 from two hospitals that could not document five organs claimed as Medicare-eligible. That smaller number is the paperwork failure. The larger number is the policy failure.
Why Organ Acquisition Costs Climbed So Fast
Organ acquisition spending inside Medicare did not inch upward. It jumped. Costs rose about 160% over 12 years, from $1.3 billion in 2011 to $3.3 billion in 2023. The number of organs rose only 77%. When spending outruns volume by that much, price, mix, and billing rules are doing a lot of the work.
| Item | Earlier Point | Later Point | Change |
| Organ acquisition spending | $1.3 billion (2011) | $3.3 billion (2023) | About +160% |
| Organs recovered | Baseline year | Later year | About +77% |
| Estimated non-Medicare use payments | — | 2017–2022 | About $380 million |
| Sample dollars paid in error cases | — | 180-case review | $2.8 million |
Those percentages do not prove fraud by themselves. They do prove that the cost per organ, or the way costs are allocated, moved faster than supply. Hospitals face real expenses when a donor case begins. Operating rooms stay open. Staff stay late. Testing happens on a clock. None of that is imaginary. The question is who should pay when the organ never reaches a Medicare patient.
I’ve found that public programs get into trouble when a temporary convenience hardens into a permanent shortcut. Assuming the recipient will be a Medicare patient is convenient. Confirming it is work. Work costs staff time. Staff time is a line item. So the shortcut survives.
The Sample That Makes The Estimate Feel Real
A national estimate can feel abstract until you walk through the sample. One hundred eighty cases. Fifty-five misses. That is more than a bad week. That is nearly one in three sampled organs billed as Medicare-eligible without a Medicare-covered transplant at the end of the chain.
- 43 organs went to patients outside Medicare coverage
- 11 organs were discarded or used for research
- 1 billed donor case involved a person who was still alive
- Two hospitals could not document five claimed organs
The living-donor mix-up is the detail people will repeat at dinner. Fair enough. It is memorable. But the 43 organs that went to non-Medicare patients are the structural story. Private insurance, other public programs, or self-pay situations can absorb a transplant. If Medicare still pays the acquisition cost, Medicare has subsidized someone else’s case. That may be compassionate in a human sense. It is not what the statute described.
Research use and discarded organs sit in a gray moral zone. Research can save future patients. Discard happens because matching fails, quality falls, or logistics collapse. Medicine is messy. Billing should still match the legal rule. If the rule says Medicare pays when the organ serves a Medicare transplant, then research and discard are not automatic Medicare bills. Unless Congress writes a different rule. It has not, at least not in the form this audit applied.
Why Recovery Was Mostly Off The Table
People hear $380 million and want a refund check. I get it. Auditors said no, not for the big number, because hospitals generally followed the written guidance. That is an important distinction. A bad rule followed correctly is still a bad rule. It is not the same as a forged invoice.
The $154,210 recommended recovery is the opposite case. Missing documentation is something a hospital can fix and something an auditor can score. Five organs. Two hospitals. Tiny next to the estimate. Useful as a signal. If you cannot show the organ existed as billed, you should not keep the money. That part is simple.
In my view, leaving the large estimate unrecovered is legally cautious and politically incomplete. Cautious because changing the deal after hospitals complied looks like a bait and switch. Incomplete because the public is still holding the tab for a design everyone already knew was leaky.
The 2021 Repair That Never Landed
Here is the part that bothers me more than the sample math. The agency saw the hole. It proposed to close it. Hospitals said revenue would drop. The proposal went away. If you work around budgets long enough, you recognize that conversation. It is the same conversation that keeps outdated formulas alive in housing, defense, and education. The incumbent payment stream becomes a constituency.
Could hospitals lose money under a tighter rule? Yes. Some acquisition costs would shift to other payers or stay with the hospital. That is the point of aligning payment with the actual recipient. If a private plan covers the transplant, the private plan can be asked to cover the related acquisition cost. If an organ is discarded, the system can decide whether a separate public grant should fund stand-by capacity. What we have now is a blur. Blurs are expensive.
I am not unsympathetic to transplant programs. They run on thin timing and high stress. A donor case can appear at 2 a.m. Teams scramble. An organ can look viable and then fail inspection. Asking those teams to also become insurance detectives is not free. A smarter fix would build the verification into the transplant center handoff, not into the operating room at midnight.
Who Ends Up Subsidizing Whom
When Medicare pays for an organ that goes to a non-Medicare patient, Medicare beneficiaries and taxpayers fund part of another person’s care. Sometimes that other person is privately insured. Sometimes the organ never becomes care at all. Either way, the cross-subsidy is quiet. Quiet subsidies last longer than loud ones.
There is a fairness argument on both sides. One side says a donated organ is a public good and the public program should keep the machinery running. The other side says a public insurance program for the elderly and certain disabled people should not automatically underwrite every donor case in the country. Both arguments can be made in good faith. Only one matches the current legal sentence the auditors used.
A payment rule that assumes the beneficiary instead of checking the beneficiary will keep producing the same surprise.
I’ve sat with enough budget tables to know that “assume” is a dangerous verb. Assume volume. Assume mix. Assume the other payer will show up later. Later often never arrives.
What Hospitals Argue, And What Holds Up
Hospital finance teams will say organ procurement is a shared infrastructure cost. You cannot always know the final recipient when the first incision is made. True. They will say underpayment threatens programs in smaller markets. Also possible. They will say administrative tracking across centers is messy. Definitely true.
What holds up less well is the idea that uncertainty must default to Medicare. Uncertainty can default to a clearinghouse. Transplant centers already track recipients, coverage, and outcomes. That is how waitlists and billing already function after the surgery. Connecting acquisition cost to the final coverage file is an information problem, not a miracle.
- Record the organ and the sending hospital.
- Record the receiving center and the recipient’s coverage.
- Allocate acquisition cost to the payer that covered the transplant.
- Create a narrow exception process for research, discard, and true unknowns.
- Audit the exceptions instead of the entire default.
That list is not poetry. It is plumbing. Plumbing is how you stop a $380 million drip.
Discarded Organs Are Not A Side Note
Eleven sampled organs were discarded or used for research. Nationally, discard is not rare, especially for kidneys that look marginal on paper. Clinicians argue about whether discard rates are too high. That debate is real. It is also separate from who pays the bill when discard happens.
If Medicare automatically pays, the program absorbs the cost of matching failures and quality calls. If another fund pays, the incentive to improve logistics sits somewhere else. I do not pretend a billing change alone will cut discard rates. I do think mixing discard costs into a Medicare-patient rule makes the true price of the system harder to see.
Research use raises a cleaner question. Research is valuable. Value does not mint a Medicare entitlement by itself. If the country wants a research set-aside, write one. Hide it inside acquisition billing and you will keep finding it in audits.
The Living Case And What It Signals
One billed case involved a person who was still alive. That should not happen. Full stop. It may be a coding disaster, a mismatched identifier, or a file that never got closed. Whatever the mechanics, it tells you the control environment has gaps wide enough for a category error that large.
People will use that one case to say the whole field is sloppy. That overreaches. Transplant medicine is full of careful people working ugly hours. A payment file can be sloppy while a surgical team is not. Still, payment files are how public money moves. They deserve the same seriousness as the clinical checklist.
Cost Growth Is The Backdrop, Not The Villain
A 160% rise in acquisition spending against a 77% rise in organs is the backdrop that makes the loophole sting. If costs had been flat, a $380 million leak would still be wrong, but it would look like a contained defect. Instead it sits inside a bill that already doubled-plus.
Why did unit costs climb? Labor. Testing. Transportation. More complex donors. More regulatory process. More overhead allocated into the organ cost center. Some of that is medical progress. Some of that is the way hospital accounting assigns shared costs. When a cost center becomes a reliable reimbursement magnet, allocations have a way of drifting toward it. That is not unique to organs. It is a classic hospital finance pattern.
I have found that the phrase “cost report” puts civilians to sleep and keeps specialists employed. Fair. The cost report is where assumptions become dollars. If the assumption is that the organ is Medicare’s, the dollar follows the assumption.
What A Serious Fix Would Look Like
Close the assumption. Require recipient-level coverage confirmation before the acquisition cost stays on the Medicare book. Give hospitals a short settlement window after transplant so they are not guessing in the moment. Publish discard and research shares so the public can see how much of the bill is not a completed Medicare transplant.
Protect small programs with a transition. If a rural center would lose a chunk of revenue overnight, phase the change. Sudden cliffs create political death for otherwise decent rules. We already watched a proposal die once. Repeating the same rollout mistake would be theater.
And please, build the check where the data already lives. Transplant centers know who received the organ. Payers know who was billed for the implant. Connecting those two files is not romantic work. It is the only work that makes the statute real.
Why This Story Keeps Its Grip
Organ donation carries a moral charge that ordinary invoices do not. Families say yes at the worst moment of their lives. Surgeons move fast. Patients wait for a second chance. Into that charged scene walks a reimbursement rule written for convenience. The contrast is stark. That is why the audit travels.
It would be cheap to sneer at every hospital. It would also be sloppy. The more precise complaint is that a public program used a shortcut, learned the shortcut was costly, tried to retire the shortcut, then left the shortcut in place after the revenue objection landed. That sequence is familiar far beyond transplant wards.
If you care about Medicare’s long-term math, this is not a curiosity. Acquisition costs are one corner of a larger bill. Corners add up. A program that cannot match a donated organ to the correct payer will have trouble with harder matching problems. This is a relatively clean test. The organ either went to a Medicare patient or it did not. The payment either followed that fact or it did not.
I keep thinking about the guidance that said, in effect, don’t check. Don’t check is easy. Don’t check is how $2.8 million in a sample becomes $380 million in an estimate. Don’t check is how a 2021 warning becomes a 2026 shrug. Checking would not end donation. It would end a habit.
Maybe the next proposal will survive the comment file. Maybe it will get watered down into a study. Maybe nothing moves until the cost line makes another ugly jump. I would rather see a boring correction now than another colorful audit later. Boring corrections are how public programs stay solvent enough to do the one job people actually want them to do: pay for covered care, for covered patients, at a price the books can explain.
Until that correction lands, the loophole stays on life support. The phrase is almost too neat. It also happens to be accurate. A rule that should have been retired is still billing. The organs keep moving. The invoices keep moving with them. And a share of those invoices still land on Medicare when the recipient never did.
